Sign in
Active, not recruitingNo phase

Autus Valve Continued Access Study (CAS)

Key facts

Who runs it
Edwards Lifesciences
Where
Ann Arbor, United StatesSee the site
Trial code
Status
Active, not recruiting
People taking part
4 people enrolled
Started
27 Jul 2026
Expected to end
30 Apr 2036
Type of study
Interventional
Treatments tested
  • Pulmonary Valve Replacement Surgery
Record updated
20 October 2026

Who can take part

Age
18 months to 16 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (27)Hide the full registry criteria

Who can take part

  • Age 18 months to 16 years
  • Male or female
  • Subject has a native or repaired right ventricular outflow tract
  • Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon)
  • Subject has at least one of the following echocardiographic findings:; Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg); Moderate or greater pulmonary regurgitation; Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation
  • Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter)
  • Subject and parent/legal representative, where appropriate, are willing to provide informed written consent
  • Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits

Who cannot take part

  • Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses
  • Subject is participating in an investigational study of a new drug, biologic, or device at the time of study screening; -
  • Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg)
  • Subject has a known history of pulmonary atresia and major aortopulmonary collaterals
  • Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics)
  • Subject has active endocarditis or a history of infective endocarditis
  • Subject has a known history of hypersensitivity to anticoagulants and antiplatelet drugs
  • Subject has a known history of autoimmune disease or receives immunosuppressant and/or immunostimulant drugs, and the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes
  • Subject needs emergency cardiac or vascular surgery or intervention
  • Subject has a known history of renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease
  • Subject has a known history of leukopenia (defined as a white blood cell [WBC] count <3.5 x 103/µL)
  • Subject has a known history of acute or chronic anemia (defined as hemoglobin [Hgb] <10.0 g/dl or 6 mmol/L)
  • Subject has a known history of thrombocytopenia (defined as platelet count <50 x 103/µL)
  • Subject requires valve replacement in a non-pulmonary position
  • Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years)
  • Subject has significant peripheral pulmonary artery stenosis
  • Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years
  • Subject or parent/legal representative refuses blood transfusions
  • Subject has medical, social, or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures

Where in United States

  • University of Michigan/Mott Children's HospitalAnn Arbor, United States

About the trial

What the trial wants to find out

Prospective, single-arm, multi-center, continued access study of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implantation, at hospital discharge, 30 days, 6 months, and annually through 10 years.

Read full original descriptionShow less

The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject.

The group in the trial

  • Autus Valve ArmTreatment being tested

    Pulmonary Valve Replacement Surgery with the Autus Valve

    Treatment: Pulmonary Valve Replacement Surgery

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Autus Size-Adjustable Valve for Surgical Pulmonary Valve Replacement Continued Access Study
Record updated
20 October 2026